Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Renal Cell Carcinoma
Management of Renal Cell Carcinoma (RCC)
Category
  • Kidney Cancer
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Updates: Management of Metastatic Kidney Cancer
Despite significant improvements in response and survival with first-line therapies, progression is universal in patients with metastatic renal cell carcinoma (RCC) requiring second, third, fourth, or further lines of therapy.
Category
  • Kidney Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Biomarker Testing for Immunotherapy
Recommendations and requirements for biomarker testing vary by the type of immune checkpoint inhibitor (ICI), specific tumor characteristics, and treatment setting.
Category
  • Bladder Cancer
  • Colorectal Cancer
  • Gynecologic Cancers
  • Kidney Cancer
  • Lung Cancers
  • Melanoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Kidney Cancer
For patients with advanced RCC, several factors are taken into consideration to help determine which systemic regimen to consider in the first-line and subsequent line therapy. It is important for clinicians to understand when to use regimens for their patient’s unique clinical situation and how to treatment for patients with metastatic RCC requiring second, third, fourth, or further lines of therapy.
Category
  • Kidney Cancer
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Event date October 16, 2019